The benefits of SGLT2 inhibitors on kidney disease progression in individuals irrespective of diabetes or albuminuria status ...

Patients with T2D and inflammatory arthritis who received GLP-1 RAs vs SGLT2 inhibitors had lower rates of hypoglycemia, serious infections, and AKI.

The first meta-analysis analyzed 70,361 participants from 10 randomized trials, and found those allocated to receive an SGLT2 ...

A heart failure polypill was not only associated with better adherence to guideline-directed medicines but also better ...

Although SGLT2 inhibitors are standard-of-care treatments for CKD, type 2 diabetes, and heart failure (HF), the drugs are underutilized in clinical practice.

NEW ORLEANS, LA—Sodium-glucose cotransporter 2 (SGLT2) inhibition does not seem to be a solution to the problem of arrhythmia ...

Adding an investigational nonsteroidal mineralocorticoid receptor antagonist (MRA) to an SGLT2 inhibitor led to a superior ...

The results of two large-scale studies demonstrate that sodium-glucose co-transporter 2 (SGLT2) inhibitors significantly ...

To address knowledge gaps, investigators conducted a meta-analysis of more than 70,000 patients in 10 trials of SGLT2 inhibitors vs placebo to determine the relative risks of CKD progression across ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. SGLT2 inhibitors do not reduce risk for death or other ...

Using SGLT2 inhibitors in the first-line treatment of type 2 diabetes lowered some cardiovascular risk, a claims database study showed. The combined 12-month risk for myocardial infarction (MI), ...

The SGLT2 inhibitors market is driven by the rising prevalence of diabetes and demand for effective antidiabetic therapies ...